Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function

Virology

Volumn 386, Issue 2, 2009, Pages 448-461

  Chen, Lee Wen ^a,b   Raghavan, Vineetha ^b   Chang, Pey Jium ^b   Shedd, Duane ^b   Heston, Lee ^b   Delecluse, Henri Jacques ^c   Miller, George ^b  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

DNA binding; EBV Rta

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; PHENYLALANINE; PROTEIN RTA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; EPSTEIN BARR VIRUS; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CELL LINE, TUMOR; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR SEQUENCE DATA; PHENYLALANINE; POINT MUTATION; PROTEIN BINDING; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 62749132855     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.01.022     Document Type: Article

References (79)

1. Adamson A.L., and Kenney S.C. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251 1 (1998) 187-197
2. Adamson A.L., Darr D., Holley-Guthrie E., Johnson R.A., Mauser A., Swenson J., and Kenney S. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74 3 (2000) 1224-1233
3. Ahmed S.I., Wibowo F., Gembitsky D.S., Bozso Z., Murphy R.F., and Lovas S. Importance of the C-terminal phenylalanine of gastrin for binding to the human CCK(2) receptor. J. Pept. Res. 58 4 (2001) 332-337
4. Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes 13 1 (2006) 12-16
5. Bartkiewicz M., Gold H., and Altman S. Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells. Genes Dev. 3 4 (1989) 488-499
6. Calderwood M.A., Holthaus A.M., and Johannsen E. The Epstein-Barr virus LF2 protein inhibits viral replication. J. Virol. 82 17 (2008) 8509-8519
7. Carey M., Kolman J., Katz D.A., Gradoville L., Barberis L., and Miller G. Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA. J. Virol. 66 8 (1992) 4803-4813
8. Chang P.J., and Miller G. Autoregulation of DNA binding and protein stability of Kaposi's sarcoma-associated herpesvirus ORF50 protein. J. Virol. 78 19 (2004) 10657-10673
9. Chang P.J., Shedd D., Gradoville L., Cho M.S., Chen L.W., Chang J., and Miller G. Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J. Virol. 76 7 (2002) 3168-3178
10. Chang L.K., Lee Y.H., Cheng T.S., Hong Y.R., Lu P.J., Wang J.J., Wang W.H., Kuo C.W., Li S.S., and Liu S.T. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J. Biol. Chem. 279 37 (2004) 38803-38812
11. Chang L.K., Chung J.Y., Hong Y.R., Ichimura T., Nakao M., and Liu S.T. Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res. 33 20 (2005) 6528-6539
12. Chang L.K., Liu S.T., Kuo C.W., Wang W.H., Chuang J.Y., Bianchi E., and Hong Y.R. Enhancement of transactivation activity of Rta of Epstein-Barr virus by RanBPM. J. Mol. Biol. 379 2 (2008) 231-242
13. Chang P.-J., Shedd D., and Miller G. A mobile functional region of Kaposi's sarcoma-associated herpesvirus ORF50 protein independently regulates DNA binding and protein abundance. J. Virol. 82 (2008) 9700-9716
14. Chen L.W., Chang P.J., Delecluse H.J., and Miller G. Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J. Virol. 79 15 (2005) 9635-9650
15. Chua H.H., Lee H.H., Chang S.S., Lu C.C., Yeh T.H., Hsu T.Y., Cheng T.H., Cheng J.T., Chen M.R., and Tsai C.H. Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J. Virol. 81 5 (2007) 2459-2471
16. Clark C., Bast D., Sharp A.M., St Hilaire P.M., Agha R., Stein P.E., Toone E.J., Read R.J., and Brunton J.L. Phenylalanine 30 plays an important role in receptor binding of verotoxin-1. Mol. Microbiol. 19 4 (1996) 891-899
17. Countryman J., and Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4085-4089
18. Countryman J., Jenson H., Seibl R., Wolf H., and Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61 12 (1987) 3672-3679
19. Cress W.D., and Triezenberg S.J. Critical structural elements of the VP16 transcriptional activation domain. Science 251 4989 (1991) 87-90
20. Daikoku T., Kudoh A., Fujita M., Sugaya Y., Isomura H., Shirata N., and Tsurumi T. Architecture of replication compartments formed during Epstein-Barr virus lytic replication. J. Virol. 79 6 (2005) 3409-3418
21. Darr C.D., Mauser A., and Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75 13 (2001) 6135-6142
22. Decaussin G., Leclerc V., and Ooka T. The lytic cycle of Epstein-Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame. J. Virol. 69 11 (1995) 7309-7314
23. Deng Z., Chen C.J., Zerby D., Delecluse H.J., and Lieberman P.M. Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation. J. Virol. 75 21 (2001) 10334-10347
24. DeWire S.M., McVoy M.A., and Damania B. Kinetics of expression of rhesus monkey rhadinovirus (RRV) and identification and characterization of a polycistronic transcript encoding the RRV Orf50/Rta, RRV R8, and R8.1 genes. J. Virol. 76 19 (2002) 9819-9831
25. Dowd C.S., Leavitt S., Babcock G., Godillot A.P., Van Ryk D., Canziani G.A., Sodroski J., Freire E., and Chaiken I.M. Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry 41 22 (2002) 7038-7046
26. Ehlers M., Grotzinger J., Fischer M., Bos H.K., Brakenhoff J.P., and Rose-John S. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. J. Interferon Cytokine Res. 16 8 (1996) 569-576
27. El-Guindy A., Heston L., Delecluse H.J., and Miller G. Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes. J. Virol. 81 7 (2007) 3303-3316
28. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., and Delecluse H.J. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19 12 (2000) 3080-3089
29. Fixman E.D., Hayward G.S., and Hayward S.D. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66 8 (1992) 5030-5039
30. Fixman E.D., Hayward G.S., and Hayward S.D. Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J. Virol. 69 5 (1995) 2998-3006
31. Francis A., Ragoczy T., Gradoville L., El-Guindy A., and Miller G. Amino acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of lytic cycle genes and synergy with the EBV Rta transactivator. J. Virol. 73 6 (1999) 4543-4551
32. Furnari F.B., Adams M.D., and Pagano J.S. Regulation of the Epstein-Barr virus DNA polymerase gene. J. Virol. 66 5 (1992) 2837-2845
33. Geser A., de The G., Lenoir G., Day N.E., and Williams E.H. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer 29 4 (1982) 397-400
34. Grimm S., and Baeuerle P.A. The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. Biochem. J. 290 Pt 2 (1993) 297-308
35. Gruffat H., Manet E., Rigolet A., and Sergeant A. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18 23 (1990) 6835-6843
36. Gruffat H., Duran N., Buisson M., Wild F., Buckland R., and Sergeant A. Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J. Virol. 66 1 (1992) 46-52
37. Hammerschmidt W., and Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55 3 (1988) 427-433
38. Hardwick J.M., Lieberman P.M., and Hayward S.D. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62 7 (1988) 2274-2284
39. Hardwick J.M., Tse L., Applegren N., Nicholas J., and Veliuona M.A. The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16. J. Virol. 66 9 (1992) 5500-5508
40. Heston L., Rabson M., Brown N., and Miller G. New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature 295 5845 (1982) 160-163
41. Holley-Guthrie E.A., Quinlivan E.B., Mar E.C., and Kenney S. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64 8 (1990) 3753-3759
42. Hoshikawa Y., Satoh Y., Murakami M., Maeta M., Kaibara N., Ito H., Kurata T., and Sairenji T. Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma. J. Med. Virol. 66 3 (2002) 351-359
43. Hupp T.R., Meek D.W., Midgley C.A., and Lane D.P. Regulation of the specific DNA binding function of p53. Cell 71 5 (1992) 875-886
44. Jayaraman J., and Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81 7 (1995) 1021-1029
45. Katz D.A., Baumann R.P., Sun R., Kolman J.L., Taylor N., and Miller G. Viral proteins associated with the Epstein-Barr virus transactivator, ZEBRA. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 282-378
46. Klein G. In: Epstein M.A., and Achong B.G. (Eds). The Relationship Of The Virus To Nasopharyngeal Carcinoma (1979), Springer-Verlag, Berlin
47. Komano J., Sugiura M., and Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J. Virol. 72 11 (1998) 9150-9156
48. Kurosu T., and Peterlin B.M. VP16 and ubiquitin; binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes. Curr. Biol. 14 12 (2004) 1112-1116
49. Lieberman P.M., Hardwick J.M., and Hayward S.D. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J. Virol. 63 7 (1989) 3040-3050
50. Lieberman P.M., Schmidt M.C., Kao C.C., and Berk A.J. Two distinct domains in the yeast transcription factor IID and evidence for a TATA box-induced conformational change. Mol. Cell. Biol. 11 1 (1991) 63-74
51. Lin R.J., Blumenkranz M.S., Binkley J., Wu K., and Vollrath D. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am. J. Ophthalmol. 142 5 (2006) 839-848
52. Liu C., Sista N.D., and Pagano J.S. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J. Virol. 70 4 (1996) 2545-2555
53. Lukac D.M., Renne R., Kirshner J.R., and Ganem D. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252 2 (1998) 304-312
54. Manet E., Gruffat H., Trescol-Biemont M.C., Moreno N., Chambard P., Giot J.F., and Sergeant A. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8 6 (1989) 1819-1826
55. Manet E., Rigolet A., Gruffat H., Giot J.F., and Sergeant A. Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res. 19 10 (1991) 2661-2667
56. Manet E., Allera C., Gruffat H., Mikaelian I., Rigolet A., and Sergeant A. The acidic activation domain of the Epstein-Barr virus transcription factor R interacts in vitro with both TBP and TFIIB and is cell-specifically potentiated by a proline-rich region. Gene Expr. 3 1 (1993) 49-59
57. Menezes J., Leibold W., Klein G., and Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22 4 (1975) 276-284
58. Mosser D.D., Theodorakis N.G., and Morimoto R.I. Coordinate changes in heat shock element-binding activity and HSP70 gene transcription rates in human cells. Mol. Cell. Biol. 8 11 (1988) 4736-4744
59. Muratani M., and Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat. Rev., Mol. Cell Biol. 4 3 (2003) 192-201
60. Park R., Heston L., Shedd D., Delecluse H.J., and Miller G. Mutations of amino acids in the DNA-recognition domain of Epstein-Barr virus ZEBRA protein alter its sub-nuclear localization and affect formation of replication compartments. Virology 382 2 (2008) 145-162
61. Pearson G.R., Vroman B., Chase B., Sculley T., Hummel M., and Kieff E. Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J. Virol. 47 1 (1983) 193-201
62. Quinlivan E.B., Holley-Guthrie E.A., Norris M., Gutsch D., Bachenheimer S.L., and Kenney S.C. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21 14 (1993) 1999-2007
63. Ragoczy T., and Miller G. Role of the Epstein-Barr virus Rta protein in activation of distinct classes of viral lytic cycle genes. J. Virol. 73 12 (1999) 9858-9866
64. Ragoczy T., and Miller G. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J. Virol. 75 11 (2001) 5240-5251
65. Ragoczy T., Heston L., and Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72 10 (1998) 7978-7984
66. Regier J.L., Shen F., and Triezenberg S.J. Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator. Proc. Natl. Acad. Sci. U.S.A. 90 3 (1993) 883-887
67. Rooney C., Taylor N., Countryman J., Jenson H., Kolman J., and Miller G. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. U.S.A. 85 24 (1988) 9801-9805
68. Sanchez-Garcia I., Osada H., Forster A., and Rabbitts T.H. The cysteine-rich LIM domains inhibit DNA binding by the associated homeodomain in Isl-1. EMBO J. 12 11 (1993) 4243-4250
69. Serio T.R., Angeloni A., Kolman J.L., Gradoville L., Sun R., Katz D.A., Van Grunsven W., Middeldorp J., and Miller G. Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21). J. Virol. 70 11 (1996) 8047-8054
70. Sun R., Lin S.F., Gradoville L., Yuan Y., Zhu F., and Miller G. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. U.S.A. 95 18 (1998) 10866-10871
71. Swenson J.J., Mauser A.E., Kaufmann W.K., and Kenney S.C. The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J. Virol. 73 8 (1999) 6540-6550
72. Swenson J.J., Holley-Guthrie E., and Kenney S.C. Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J. Virol. 75 13 (2001) 6228-6234
73. Takada K., Shimizu N., Sakuma S., and Ono Y. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57 3 (1986) 1016-1022
74. Thompson M.P., and Kurzrock R. Epstein-Barr virus and cancer. Clin. Cancer Res. 10 3 (2004) 803-821
75. Whitehouse A., Carr I.M., Griffiths J.C., and Meredith D.M. The herpesvirus saimiri ORF50 gene, encoding a transcriptional activator homologous to the Epstein-Barr virus R protein, is transcribed from two distinct promoters of different temporal phases. J. Virol. 71 3 (1997) 2550-2554
76. Wu T.T., Usherwood E.J., Stewart J.P., Nash A.A., and Sun R. Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency. J. Virol. 74 8 (2000) 3659-3667
77. Zacny V.L., Wilson J., and Pagano J.S. The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle. J. Virol. 72 10 (1998) 8043-8051
78. Zalani S., Holley-Guthrie E., and Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. U.S.A. 93 17 (1996) 9194-9199
79. Zeng Y., Zhang L.G., Wu Y.C., Huang Y.S., Huang N.Q., Li J.Y., Wang Y.B., Jiang M.K., Fang Z., and Meng N.N. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int. J. Cancer 36 5 (1985) 545-547